Immunome (IMNM)
(Delayed Data from NSDQ)
$15.20 USD
+0.05 (0.33%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $15.20 0.00 (0.00%) 7:28 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMNM 15.20 +0.05(0.33%)
Will IMNM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMNM
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for April 4th
Company News for Apr 2, 2024
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
Other News for IMNM
Evaluating Immunome: Insights From 4 Financial Analysts
Immunome initiated with bullish view at Piper Sandler, here's why
Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs
Video: Wednesday 5/22 Insider Buying Report: IMNM, CMI
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying